CVD Clinical Trial
Official title:
Phase 4 Study of Argatroban for Preventing Restenosis After Extracranial Vertebral Artery Stenting
Argatroban is a selective thrombin inhibitor, and previous study had suggested that argatroban use post percutaneous coronary intervention could potentially prevent reocclusion. But there has no study on large sample of argatroban treated restenosis vertebral artery stenting. This study will test the safety and efficacy of the argatroban on prevent Occlusion and Restenosis in patients with Extracranial vertebral Artery Stenting.
The risk of restenosis post intracranial and extracranial artery stenting is 20-40%, therefore, in the past, aspirin and clopidogrel were performed as anticoagulant therapy post stenting.But this treatment had limited effectiveness upon restenosis. Argatroban is a selective thrombin inhibitor, and previous study had suggested that argatroban use post PCI could potentially prevent reocclusion. But there has no study on large sample of argatroban treated Occlusion and Restenosis Extracranial vertebral Artery Stenting. This study will test the safety and efficacy of the argatroban on prevent Occlusion and Restenosis in patients with Extracranial vertebral Artery Stenting. ;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02480504 -
Effects of a 5:2 Diet on Weight Loss and Cardiovascular Risk Factors in Obesity
|
N/A | |
| Completed |
NCT02440893 -
Understanding the Effect of Metformin on Corus CAD (or ASGES)
|
||
| Completed |
NCT01486030 -
Effect of Exercise Stress Testing on Peripheral Gene Expression Using Corus CAD (or ASGES) Diagnostic Test
|
||
| Active, not recruiting |
NCT00038727 -
Diabetes Prevention Program Outcomes Study
|
Phase 3 | |
| Completed |
NCT03967678 -
Omega (n)-3 PUFA Enriched Beef & Health Outcomes.
|
N/A | |
| Completed |
NCT01251302 -
Utility of a Molecular Personalized Coronary Gene Expression Test (Corus CAD or ASGES) on Cardiology Practice Pattern
|
||
| Not yet recruiting |
NCT05716659 -
EEG/MECG/EMG Evaluating the Severity of Aortic Stenosis, Heart Failure and Ischemic Stroke Through an Artificial Intelligenceassisted System.
|
||
| Withdrawn |
NCT02158754 -
Clinician Utilization of Corus CAD (or ASGES) in Primary Care Provider Decision Making
|
||
| Completed |
NCT01077388 -
e-Care for Heart Wellness
|
Phase 3 | |
| Completed |
NCT04384029 -
The Geneva Covid-19 CVD Study
|
||
| Active, not recruiting |
NCT02382822 -
Copenhagen Co-morbidity in HIV Infection Study
|
||
| Active, not recruiting |
NCT01825668 -
Effect of Plant Sterol Enriched Milk on Plasma Lipid Levels of Humans Breast-fed During Infancy
|
N/A | |
| Completed |
NCT02223286 -
Understanding Clinician Utilization of Corus CAD (Age/Sex/Gene Expression Score - ASGES) in Clinical Decision Making
|
N/A | |
| Completed |
NCT00289237 -
Lifestyle Intervention in a General Population for Prevention of Ischaemic Heart Disease
|
N/A | |
| Not yet recruiting |
NCT03658031 -
Effect of Dapagliflozin on the Progression From Prediabetes to T2DM in Subjects With Myocardial Infarction
|
Phase 3 | |
| Completed |
NCT03636529 -
Tart Cherry Juice and Markers of Inflammation, CVD, and Diabetes
|
N/A | |
| Completed |
NCT00500708 -
Diagnostic Investigation of Sudden Cardiac Event Risk
|
N/A | |
| Completed |
NCT00500617 -
Personalized Risk Evaluation and Diagnosis (Using Corus CAD or ASGES) in the Coronary Tree
|
||
| Completed |
NCT01255852 -
Atorvastatin for Preventing Occlusion and Restenosis After Intracranial Artery Stenting
|
Phase 4 | |
| Completed |
NCT00583297 -
Genetic Substudy of the Alternans Before Cardioverter Defibrillator (ABCD) Trial
|
N/A |